## 1. Phylogeny

Cyclin‑dependent kinase 9 (CDK9), encoded by the CDK9 gene (also known as CDC2L4 or TAK), is a prominent member of the cyclin‑dependent kinase family that belongs to the larger CMGC group of serine/threonine kinases. CDK9 is phylogenetically clustered with a subgroup of kinases that regulate transcription, including CDK7, CDK8, CDK12, and CDK13, rather than those primarily involved in cell cycle progression. This evolutionary grouping reflects a functional specialization; while cell cycle CDKs (such as CDK1 and CDK2) exhibit periodic activation during cell division, transcriptional CDKs like CDK9 are constitutively present in the nucleus to sustain essential gene expression even in non-dividing cells (alrouji2025mechanisticrolesof pages 1-2, alrouji2025mechanisticrolesof pages 2-5).

Orthologous counterparts of CDK9 are found across a broad spectrum of eukaryotic organisms—from yeast to mammals—underscoring its ancient origin and the evolutionary indispensability of its role in transcription. Yeast homologs such as Bur1 and Ctk1 have been shown to perform similar functions in transcription elongation, implying that the basic mechanism of CDK9‐mediated regulation of RNA polymerase II elongation dates back to early eukaryotes (paparidis2017theemergingpicture pages 6-8, greenleaf2019humancdk12and pages 19-22). In mammals, two isoforms of CDK9 have been identified—one of approximately 42 kDa and another of about 55 kDa—both of which are conserved across species, although they may show tissue‐specific expression patterns or subcellular localization differences (morales2016overviewofcdk9 pages 1-2).

The conservation of CDK9 across species indicates its fundamental role in integrating extracellular signals into precise transcriptional responses. Given its deep evolutionary roots, CDK9 is an integral component of the transcriptional machinery that has been maintained since the last eukaryotic common ancestor. This conservation also hints at the tightly regulated balance required for proper gene expression, as any perturbation in such ancient and conserved proteins could have severe cellular consequences (alrouji2025mechanisticrolesof pages 1-2, paparidis2017theemergingpicture pages 1-2). Moreover, the transcriptional CDKs collectively form an evolutionary core that is distinct from kinases of the cell cycle; their phylogenetic separation is a reflection of divergent regulatory needs in transcription versus cell division, with CDK9 being central to processes such as transcription elongation and co‑transcriptional mRNA processing (alrouji2025mechanisticrolesof pages 2-5, isa2017theroleof pages 17-20).

## 2. Reaction Catalyzed

CDK9 functions as a protein kinase that catalyzes the transfer of the γ‑phosphate group from ATP to specific serine or threonine residues within its substrate proteins. The core reaction can be summarized as follows: ATP + [protein]‑OH → ADP + [protein]-O‑phosphate + H⁺. In this reaction, the γ‑phosphate group of ATP is transferred to the hydroxyl group of targeted amino acid residues, resulting in the formation of a phosphorylated protein product with concomitant generation of ADP (bacon2019cdk9asignaling pages 3-4).

One of the most well‐characterized substrates of CDK9 is the carboxyl‑terminal domain (CTD) of RNA polymerase II. The CTD consists of multiple tandem repeats of a heptapeptide sequence (YSPTSPS), and CDK9 specifically phosphorylates the Ser2 residue within this repeat. This phosphorylation event is critical for the release of RNA polymerase II from promoter‑proximal pausing and for its transition into productive elongation during transcription (alrouji2025mechanisticrolesof pages 1-2, parua2020dissectingthepol pages 11-12).

In addition to the CTD of RNA polymerase II, CDK9 phosphorylates several other key regulatory proteins. These include transcription elongation factors such as SUPT5H and RDBP, whose phosphorylation modifies their function by relieving their inhibitory effects on transcription elongation. Moreover, CDK9 regulates the activity of chromatin and transcription regulators like EP300, a histone acetyltransferase, MYOD1, which is crucial for muscle differentiation, as well as the androgen receptor (AR), which modulates gene expression patterns involved in cell growth. By phosphorylating these diverse substrates, CDK9 not only facilitates the progressive elongation of RNA transcripts but also coordinates a network of co‑transcriptional events that include mRNA processing and chromatin remodeling (alrouji2025mechanisticrolesof pages 1-2, bacon2019cdk9asignaling pages 3-4).

Furthermore, CDK9’s activity underpins important cytokine‑inducible transcription networks by facilitating the promoter recognition and activation of transcription factors such as RELA/p65 and STAT3. This indicates that its kinase reaction is not an isolated event but intersects with signaling pathways that govern critical cellular responses including inflammation, proliferation, and survival (alrouji2025mechanisticrolesof pages 12-14, parua2020dissectingthepol pages 16-23). In summary, the catalytic reaction of CDK9 is central to the regulation of transcription elongation and is achieved by the transfer of phosphate groups to strategic serine and threonine residues on a variety of substrates essential for high-fidelity gene expression (alrouji2025mechanisticrolesof pages 1-2, bacon2019cdk9asignaling pages 3-4).

## 3. Cofactor Requirements

The enzymatic activity of CDK9 is dependent on several critical cofactors that facilitate its kinase function. Foremost among these is the divalent metal ion magnesium (Mg²⁺), which is required for the proper coordination and stabilization of the ATP molecule within the kinase’s active site. Mg²⁺ ions assist in aligning the γ‑phosphate of ATP in the correct spatial orientation for the nucleophilic attack by the hydroxyl group of the substrate amino acid, thereby making the phosphate transfer reaction both feasible and efficient (bacon2019cdk9asignaling pages 3-4, mohammad2022bioinformaticanalysisof pages 26-29).

In addition to Mg²⁺, the kinase activity of CDK9 is contingent upon its assembly into a heterodimeric complex with specific cyclin partners. The formation of the CDK9/cyclin T complex—the canonical positive transcription elongation factor b (P‑TEFb) complex—is essential for unlocking its full catalytic potential. In certain cellular contexts, CDK9 can also partner with cyclin K, which may substitute for cyclin T to a certain extent in vitro (alrouji2025mechanisticrolesof pages 1-2, duster2021biochemicalcharacterizationof pages 28-31). This cyclin binding not only ensures the proper folding and orientation of the activation loop (T‑loop) but also induces conformational changes necessary for substrate recognition and catalysis (mandal2021targetingcdk9for pages 1-2, alrouji2025mechanisticrolesof pages 2-5).

Moreover, CDK9’s activity is modulated by its reversible sequestration in the 7SK snRNP complex. Binding of CDK9 within this ribonucleoprotein complex, together with regulatory proteins such as HEXIM1/2, LARP7, and MePCE, renders the kinase catalytically inert until release is triggered by appropriate cellular cues (alrouji2025mechanisticrolesof pages 7-9, isa2017theroleof pages 17-20). This dynamic interplay between active and inactive states constitutes a crucial regulatory mechanism in which multiple cofactors—both small ions like Mg²⁺ and larger regulatory complexes such as cyclins and 7SK snRNP components—converge to finely tune CDK9’s kinase activity.

## 4. Substrate Specificity

CDK9 displays a highly refined substrate specificity that is integral to its role in transcription regulation. Its primary target is the C‑terminal domain of RNA polymerase II, which consists of repeated YSPTSPS heptapeptide motifs. Among these repeats, phosphorylation specifically at the Ser2 residue is critical for the transition from a paused state to active elongation of the nascent mRNA transcript (alrouji2025mechanisticrolesof pages 1-2, duster2024structuralbasisof pages 1-4).

Beyond the RNA polymerase II CTD, CDK9 phosphorylates a suite of proteins that collectively modulate the transcriptional process. For instance, CDK9 targets the elongation factors DSIF and NELFE. Under basal conditions, these factors impose a negative influence on RNA polymerase II by maintaining a state of transcriptional pausing. Phosphorylation by CDK9 relieves this inhibition, facilitating the transition to productive elongation (isa2017theroleof pages 17-20, alrouji2025mechanisticrolesof pages 1-2).

Furthermore, CDK9-mediated phosphorylation extends to transcription co‑activators and regulatory proteins. EP300, a histone acetyltransferase, is activated upon phosphorylation by CDK9, thereby promoting chromatin remodeling and enhanced transcriptional initiation and elongation (alrouji2025mechanisticrolesof pages 7-9, gao2018designsynthesisand pages 172-177). Similarly, phosphorylation of MYOD1 boosts its transcriptional activity, which is a key requirement for the induction of muscle differentiation, while phosphorylation of the androgen receptor influences its promoter selectivity and drives downstream cell growth signals in certain hormone-dependent cancers (morales2016overviewofcdk9 pages 1-2, bacon2019cdk9asignaling pages 3-4).

Recent comprehensive kinase substrate analyses, such as those presented by Johnson et al. in Nature 2023, have indicated that CDK9 substrates often contain serine or threonine residues followed immediately by a proline residue. This proline-directed motif is a hallmark of many CDKs and is critical for determining substrate specificity, thereby ensuring that CDK9 discriminates its targets from those of other kinases (johnson2023anatlasof pages 1-2, mohammad2022bioinformaticanalysisof pages 22-26). The precise amino acid context around the phosphorylated residue—encompassing flanking basic or hydrophobic residues—further refines substrate recognition and catalytic efficiency (alrouji2025mechanisticrolesof pages 2-5, isa2017theroleof pages 17-20).

Collectively, the substrate specificity of CDK9 is defined by its capacity to recognize and phosphorylate key regulatory motifs within the transcriptional machinery, thereby integrating a multitude of transcriptional and co‑transcriptional events essential for robust gene expression.

## 5. Structure

Structurally, CDK9 is characterized by a bilobal kinase domain that is conserved across the cyclin‑dependent kinase family. The N‑terminal lobe is composed mainly of β‑sheet structures and contains a glycine‑rich loop (G‑loop) that plays an important role in ATP binding. In contrast, the larger C‑terminal lobe is dominated by α‑helices and harbors the catalytic site responsible for substrate phosphorylation (duster2024structuralbasisof pages 1-4, anshabo2021cdk9acomprehensive pages 1-2).

A hallmark of CDK9 is the presence of the PITALRE motif—a unique sequence feature that is essential for binding its cyclin partner. This motif facilitates the precise positioning of the activation loop (T‑loop) within the kinase domain. Binding of cyclin T induces a conformational rearrangement of the T‑loop, thereby enabling full kinase activation. Phosphorylation within this loop, often mediated by the CDK‑activating kinase CDK7, further reinforces the active conformation of CDK9 (alrouji2025mechanisticrolesof pages 1-2, paparidis2017theemergingpicture pages 6-8).

The active site of CDK9 is located in the cleft between the N‑ and C‑terminal lobes. Here, conserved catalytic residues, including those in the DFG motif, coordinate with Mg²⁺ ions to facilitate ATP binding. Mutations or chemical modifications in these conserved regions have been demonstrated to abrogate kinase activity, highlighting the essential nature of these residues for catalysis (duster2021biochemicalcharacterizationof pages 116-118, modi2022kincoreaweb pages 3-5).

Additionally, CDK9 contains flanking regions that are predicted to be intrinsically disordered. These regions likely serve as flexible platforms for protein–protein interactions, enabling CDK9 to dynamically associate with regulatory complexes such as the 7SK snRNP. The disordered segments might also play roles in modulating substrate access or in the integration of post‑translational signals that control CDK9 activity (alrouji2025mechanisticrolesof pages 7-9, duster2021biochemicalcharacterizationof pages 28-31).

High-resolution crystallographic studies and computational models have provided further insights into the structural determinants of the ATP-binding pocket. Such data have been instrumental in guiding the rational design of selective inhibitors by delineating how small molecules can access and bind within the catalytic cleft, thereby disrupting kinase activity (duster2024structuralbasisof pages 1-4, anshabo2021cdk9acomprehensive pages 2-4). These structural studies underscore the intricate interplay between the conserved kinase core and the regulatory sequences that together confer both specificity and versatility on CDK9’s function.

## 6. Regulation

The regulation of CDK9 is multifaceted and involves both activating and inhibitory mechanisms that ensure its kinase activity is tightly controlled in response to cellular signals. A primary regulatory mechanism is the obligatory formation of the heterodimeric complex between CDK9 and its cyclin partner (principally cyclin T, and in some contexts cyclin K). Cyclin binding induces a conformational change that reorganizes the activation loop into an active form, thus permitting substrate binding and catalysis (alrouji2025mechanisticrolesof pages 1-2, mandal2021targetingcdk9for pages 1-2).

Subsequent to cyclin binding, phosphorylation of a critical threonine residue in the T‑loop (commonly Thr186 in CDK9) is required to achieve maximal activation. This phosphorylation event is largely mediated by CDK7, which functions within the CDK‑activating kinase (CAK) complex. The modification of the T‑loop by CDK7 serves to stabilize the active conformation of CDK9, thereby enhancing its catalytic efficiency (mandal2021targetingcdk9for pages 2-4, isa2017theroleof pages 20-23).

Conversely, CDK9 activity is subject to negative regulation via its sequestration into the 7SK small nuclear ribonucleoprotein (snRNP) complex. Within this complex, CDK9 is inhibited by the binding of regulatory proteins—namely HEXIM1/2, LARP7, and MePCE—which interact with the kinase and its cyclin partner and effectively block the ATP binding site or induce conformational alterations that preclude substrate access (alrouji2025mechanisticrolesof pages 7-9, isa2017theroleof pages 17-20).

In addition to phosphorylation and sequestration, CDK9 is further regulated by other post‑translational modifications. Acetylation and deacetylation events have been reported to modulate the kinase’s interaction with both its substrates and regulatory partners, creating an additional layer of control over its activity. The dynamic balance between these activating modifications (phosphorylation by CDK7 and cyclin-induced conformational changes) and inhibitory events (sequestration in the 7SK snRNP complex and deacetylation) ensures that CDK9 activity is responsive to cellular conditions, such as stress and growth factor stimulation (mandal2021targetingcdk9for pages 4-5, mohammad2022bioinformaticanalysisof pages 22-26).

Furthermore, cellular signals from cytokine-inducible pathways, such as those triggered by TNF and IL‑6, can impact CDK9 activity by altering its interactions with transcription factors like RELA/p65 and STAT3. These interactions provide feedback mechanisms that couple extracellular signals to the regulation of transcription elongation, thereby integrating environmental cues with gene expression programs (bacon2019cdk9asignaling pages 3-4, alrouji2025mechanisticrolesof pages 12-14).

## 7. Function

Functionally, CDK9 is a master regulator of transcription elongation and co‑transcriptional processing. By phosphorylating the CTD of RNA polymerase II at the Ser2 position, CDK9 facilitates the release of the polymerase from promoter-proximal pausing, which is a critical checkpoint in the early stages of transcription. This phosphorylation event is pivotal for allowing RNA polymerase II to transition into a productive elongation phase, thereby ensuring the accurate synthesis of full-length mRNA transcripts (alrouji2025mechanisticrolesof pages 1-2, bacon2019cdk9asignaling pages 3-4).

In addition to directly targeting the RNA polymerase II CTD, CDK9 modulates the function of key elongation factors such as DSIF and NELFE. Under basal conditions, DSIF and NELF maintain RNA polymerase II in a paused state. Their phosphorylation by CDK9 alleviates this repression, thus acting as a molecular switch that coordinates the release of polymerase into the elongation phase (isa2017theroleof pages 17-20, alrouji2025mechanisticrolesof pages 1-2).

Beyond its canonical role in transcription elongation, CDK9 exerts influence over a wide array of co‑transcriptional processes. For instance, its role in phosphorylating EP300 enhances the activity of this histone acetyltransferase, which in turn promotes chromatin relaxation and facilitates the access of transcription machinery to DNA. This dual function—both modifying the transcription apparatus and altering chromatin dynamics—highlights CDK9’s central position in the regulation of gene expression (alrouji2025mechanisticrolesof pages 7-9, gao2018designsynthesisand pages 172-177).

Furthermore, CDK9 phosphorylates transcription factors such as MYOD1 and the androgen receptor (AR). Phosphorylation of MYOD1 increases its transcriptional activity, thereby playing a crucial role in the promotion of muscle differentiation. Similarly, the phosphorylation of AR by CDK9 modulates the receptor’s promoter selectivity, which directly impacts cell growth and proliferation, particularly in hormone-responsive tissues and cancers (morales2016overviewofcdk9 pages 1-2, bacon2019cdk9asignaling pages 3-4).

CDK9 activity is also linked to the cellular response to replication stress. An alternative complex formed by CDK9 with cyclin K has been implicated in maintaining genome integrity, as it can substitute for the classical CDK9/cyclin T complex in phosphorylating the RNA polymerase II CTD. This function is especially important in the context of replication arrest, where CDK9 facilitates cell cycle recovery and minimizes DNA damage by preventing the accumulation of single-stranded DNA at stalled replication forks (alrouji2025mechanisticrolesof pages 18-20, mohammad2022bioinformaticanalysisof pages 26-29).

In addition, CDK9’s involvement in cytokine‑inducible transcription networks—through its facilitation of promoter recognition for transcription factors such as RELA/p65 and STAT3—ensures that cells can rapidly adjust their gene expression profiles in response to external stimuli, such as inflammatory signals (alrouji2025mechanisticrolesof pages 12-14, parua2020dissectingthepol pages 16-23). These diverse roles position CDK9 at the nexus of transcriptional regulation, chromatin modification, and cell signaling pathways, rendering it essential for normal cellular function as well as for the pathogenesis of diseases like cancer and viral infections.

## 8. Other Comments

The centrality of CDK9 in orchestrating transcriptional elongation and co‑transcriptional events has rendered it an attractive target for therapeutic intervention. In various malignancies, including those driven by transcriptional addiction, overactive CDK9 contributes to the continuous expression of oncogenes and survival pathways. As a result, small‑molecule inhibitors that target the ATP‑binding site of CDK9—such as flavopiridol and SNS‑032—have been developed, and they have demonstrated potent antiproliferative effects in pre‑clinical studies (boffo2018cdk9inhibitorsin pages 1-2, mandal2021targetingcdk9for pages 29-30).

Moreover, innovative therapeutic strategies such as proteolysis‑targeting chimeras (PROTACs) have emerged, which offer a novel approach by promoting the selective degradation of CDK9 rather than merely inhibiting its enzymatic activity. These PROTACs have the potential to achieve a more sustained and selective suppression of CDK9 function, which is being rigorously evaluated in both cancer and viral pathogenesis models (king2021utilizingproteolysistargetingchimeras pages 8-14, hope2023emergingapproachesto pages 8-9).

The ability of CDK9 to form complexes with either cyclin T or cyclin K adds an additional layer of regulatory complexity. Differential regulation through these complexes allows for context‑dependent control of transcription elongation—a feature that is being actively explored for its therapeutic potential. In particular, the sequestration of CDK9 in the 7SK snRNP complex represents a critical regulatory node that could be manipulated to fine-tune its activity under pathological conditions (alrouji2025mechanisticrolesof pages 7-9, isa2017theroleof pages 17-20).

Alterations in the regulatory domains of CDK9, including mutations in its T‑loop or in regions that interface with cyclins, have been associated with dysregulated transcription and oncogenesis. Studies on mutational impacts continue to reveal insights into how even subtle alterations in CDK9’s regulatory circuitry can profoundly affect transcriptional homeostasis and cellular responses, highlighting the need for precise modulation of its activity in therapeutic settings (mandal2021targetingcdk9for pages 2-4, paparidis2017theemergingpicture pages 3-4).

In summary, the research into CDK9 remains a highly dynamic field. Its critical functions in modulating RNA polymerase II activity, chromatin remodeling, and cellular stress responses underscore its pivotal role in maintaining cellular homeostasis. Ongoing investigations aim not only to refine our understanding of CDK9’s biochemical and structural properties but also to harness this knowledge to develop next‑generation inhibitors with improved specificity and reduced side effects. These efforts are particularly important in the context of treating cancers and other diseases marked by aberrant transcriptional regulation.

## 9. References

alrouji2025mechanisticrolesof pages 1-2; alrouji2025mechanisticrolesof pages 12-14; alrouji2025mechanisticrolesof pages 18-20; alrouji2025mechanisticrolesof pages 2-5; alrouji2025mechanisticrolesof pages 7-9; bacon2019cdk9asignaling pages 3-4; boffo2018cdk9inhibitorsin pages 1-2; duster2021biochemicalcharacterizationof pages 116-118; duster2021biochemicalcharacterizationof pages 23-28; duster2021biochemicalcharacterizationof pages 28-31; duster2024structuralbasisof pages 1-4; gao2018designsynthesisand pages 172-177; greenleaf2019humancdk12and pages 19-22; hope2023emergingapproachesto pages 8-9; isa2017theroleof pages 17-20; isa2017theroleof pages 20-23; isa2017theroleof pages 23-26; johnson2023anatlasof pages 1-2; johnson2023anatlasof pages 3-4; johnson2023anatlasof pages 4-4; king2021utilizingproteolysistargetingchimeras pages 122-126; king2021utilizingproteolysistargetingchimeras pages 19-24; king2021utilizingproteolysistargetingchimeras pages 8-14; ksionsko2024mechanisticcharacterizationof pages 21-23; mandal2021targetingcdk9for pages 1-2; mandal2021targetingcdk9for pages 2-4; mandal2021targetingcdk9for pages 23-25; mandal2021targetingcdk9for pages 29-30; mandal2021targetingcdk9for pages 4-5; martinez2024paf1callostericallyactivates pages 1-5; martinez2024paf1callostericallyactivates pages 20-24; modi2022kincoreaweb pages 3-5; mohammad2022bioinformaticanalysisof pages 142-145; mohammad2022bioinformaticanalysisof pages 22-26; mohammad2022bioinformaticanalysisof pages 26-29; morales2016overviewofcdk9 pages 1-2; paparidis2017theemergingpicture pages 1-2; paparidis2017theemergingpicture pages 3-4; paparidis2017theemergingpicture pages 6-8; parua2020dissectingthepol pages 11-12; parua2020dissectingthepol pages 16-23.

References

1. (alrouji2025mechanisticrolesof pages 1-2): Mohammad Alrouji, Mohammed S. Alshammari, Saleha Anwar, Kumar Venkatesan, and Anas Shamsi. Mechanistic roles of transcriptional cyclin-dependent kinases in oncogenesis: implications for cancer therapy. Cancers, 17:1554, May 2025. URL: https://doi.org/10.3390/cancers17091554, doi:10.3390/cancers17091554. This article has 0 citations and is from a peer-reviewed journal.
2. (alrouji2025mechanisticrolesof pages 12-14): Mohammad Alrouji, Mohammed S. Alshammari, Saleha Anwar, Kumar Venkatesan, and Anas Shamsi. Mechanistic roles of transcriptional cyclin-dependent kinases in oncogenesis: implications for cancer therapy. Cancers, 17:1554, May 2025. URL: https://doi.org/10.3390/cancers17091554, doi:10.3390/cancers17091554. This article has 0 citations and is from a peer-reviewed journal.
3. (alrouji2025mechanisticrolesof pages 18-20): Mohammad Alrouji, Mohammed S. Alshammari, Saleha Anwar, Kumar Venkatesan, and Anas Shamsi. Mechanistic roles of transcriptional cyclin-dependent kinases in oncogenesis: implications for cancer therapy. Cancers, 17:1554, May 2025. URL: https://doi.org/10.3390/cancers17091554, doi:10.3390/cancers17091554. This article has 0 citations and is from a peer-reviewed journal.
4. (alrouji2025mechanisticrolesof pages 2-5): Mohammad Alrouji, Mohammed S. Alshammari, Saleha Anwar, Kumar Venkatesan, and Anas Shamsi. Mechanistic roles of transcriptional cyclin-dependent kinases in oncogenesis: implications for cancer therapy. Cancers, 17:1554, May 2025. URL: https://doi.org/10.3390/cancers17091554, doi:10.3390/cancers17091554. This article has 0 citations and is from a peer-reviewed journal.
5. (alrouji2025mechanisticrolesof pages 7-9): Mohammad Alrouji, Mohammed S. Alshammari, Saleha Anwar, Kumar Venkatesan, and Anas Shamsi. Mechanistic roles of transcriptional cyclin-dependent kinases in oncogenesis: implications for cancer therapy. Cancers, 17:1554, May 2025. URL: https://doi.org/10.3390/cancers17091554, doi:10.3390/cancers17091554. This article has 0 citations and is from a peer-reviewed journal.
6. (anshabo2021cdk9acomprehensive pages 1-2): Abel Tesfaye Anshabo, Robert Milne, Shudong Wang, and Hugo Albrecht. Cdk9: a comprehensive review of its biology, and its role as a potential target for anti-cancer agents. Frontiers in Oncology, May 2021. URL: https://doi.org/10.3389/fonc.2021.678559, doi:10.3389/fonc.2021.678559. This article has 122 citations and is from a peer-reviewed journal.
7. (anshabo2021cdk9acomprehensive pages 2-4): Abel Tesfaye Anshabo, Robert Milne, Shudong Wang, and Hugo Albrecht. Cdk9: a comprehensive review of its biology, and its role as a potential target for anti-cancer agents. Frontiers in Oncology, May 2021. URL: https://doi.org/10.3389/fonc.2021.678559, doi:10.3389/fonc.2021.678559. This article has 122 citations and is from a peer-reviewed journal.
8. (bacon2019cdk9asignaling pages 3-4): Curtis W. Bacon and Iván D’Orso. Cdk9: a signaling hub for transcriptional control. Transcription, 10:57-75, Oct 2019. URL: https://doi.org/10.1080/21541264.2018.1523668, doi:10.1080/21541264.2018.1523668. This article has 211 citations and is from a peer-reviewed journal.
9. (boffo2018cdk9inhibitorsin pages 1-2): Silvia Boffo, Angela Damato, Luigi Alfano, and Antonio Giordano. Cdk9 inhibitors in acute myeloid leukemia. Journal of Experimental & Clinical Cancer Research, Feb 2018. URL: https://doi.org/10.1186/s13046-018-0704-8, doi:10.1186/s13046-018-0704-8. This article has 168 citations.
10. (duster2021biochemicalcharacterizationof pages 116-118): RS Düster. Biochemical characterization of the human cyclin-dependent kinases cdk7 and cdk10. Unknown journal, 2021.
11. (duster2021biochemicalcharacterizationof pages 23-28): RS Düster. Biochemical characterization of the human cyclin-dependent kinases cdk7 and cdk10. Unknown journal, 2021.
12. (duster2021biochemicalcharacterizationof pages 28-31): RS Düster. Biochemical characterization of the human cyclin-dependent kinases cdk7 and cdk10. Unknown journal, 2021.
13. (duster2024structuralbasisof pages 1-4): Robert Düster, Kanchan Anand, Sophie C. Binder, Maximilian Schmitz, Karl Gatterdam, Robert P. Fisher, and Matthias Geyer. Structural basis of cdk7 activation by dual t-loop phosphorylation. BioRxiv, Feb 2024. URL: https://doi.org/10.1101/2024.02.14.580246, doi:10.1101/2024.02.14.580246. This article has 9 citations.
14. (gao2018designsynthesisand pages 172-177): R Gao. Design, synthesis, and optimisation of highly selective macrocyclic cdk9 inhibitors. Unknown journal, 2018.
15. (greenleaf2019humancdk12and pages 19-22): Arno L. Greenleaf. Human cdk12 and cdk13, multi-tasking ctd kinases for the new millenium. Transcription, 10:91-110, Oct 2019. URL: https://doi.org/10.1080/21541264.2018.1535211, doi:10.1080/21541264.2018.1535211. This article has 98 citations and is from a peer-reviewed journal.
16. (hope2023emergingapproachesto pages 8-9): Ian Hope, Jane A. Endicott, and Jessica E. Watt. Emerging approaches to cdk inhibitor development, a structural perspective. RSC Chemical Biology, 4:146-164, Jan 2023. URL: https://doi.org/10.1039/d2cb00201a, doi:10.1039/d2cb00201a. This article has 8 citations.
17. (isa2017theroleof pages 17-20): NF Isa. The role of the hsv-1 icp22 protein in regulation of expression of host cell genes. Unknown journal, 2017.
18. (isa2017theroleof pages 20-23): NF Isa. The role of the hsv-1 icp22 protein in regulation of expression of host cell genes. Unknown journal, 2017.
19. (isa2017theroleof pages 23-26): NF Isa. The role of the hsv-1 icp22 protein in regulation of expression of host cell genes. Unknown journal, 2017.
20. (johnson2023anatlasof pages 1-2): Jared L. Johnson, Tomer M. Yaron, Emily M. Huntsman, Alexander Kerelsky, Junho Song, Amit Regev, Ting-Yu Lin, Katarina Liberatore, Daniel M. Cizin, Benjamin M. Cohen, Neil Vasan, Yilun Ma, Konstantin Krismer, Jaylissa Torres Robles, Bert van de Kooij, Anne E. van Vlimmeren, Nicole Andrée-Busch, Norbert F. Käufer, Maxim V. Dorovkov, Alexey G. Ryazanov, Yuichiro Takagi, Edward R. Kastenhuber, Marcus D. Goncalves, Benjamin D. Hopkins, Olivier Elemento, Dylan J. Taatjes, Alexandre Maucuer, Akio Yamashita, Alexei Degterev, Mohamed Uduman, Jingyi Lu, Sean D. Landry, Bin Zhang, Ian Cossentino, Rune Linding, John Blenis, Peter V. Hornbeck, Benjamin E. Turk, Michael B. Yaffe, and Lewis C. Cantley. An atlas of substrate specificities for the human serine/threonine kinome. Nature, 613:759-766, Jan 2023. URL: https://doi.org/10.1038/s41586-022-05575-3, doi:10.1038/s41586-022-05575-3. This article has 416 citations and is from a highest quality peer-reviewed journal.
21. (johnson2023anatlasof pages 3-4): Jared L. Johnson, Tomer M. Yaron, Emily M. Huntsman, Alexander Kerelsky, Junho Song, Amit Regev, Ting-Yu Lin, Katarina Liberatore, Daniel M. Cizin, Benjamin M. Cohen, Neil Vasan, Yilun Ma, Konstantin Krismer, Jaylissa Torres Robles, Bert van de Kooij, Anne E. van Vlimmeren, Nicole Andrée-Busch, Norbert F. Käufer, Maxim V. Dorovkov, Alexey G. Ryazanov, Yuichiro Takagi, Edward R. Kastenhuber, Marcus D. Goncalves, Benjamin D. Hopkins, Olivier Elemento, Dylan J. Taatjes, Alexandre Maucuer, Akio Yamashita, Alexei Degterev, Mohamed Uduman, Jingyi Lu, Sean D. Landry, Bin Zhang, Ian Cossentino, Rune Linding, John Blenis, Peter V. Hornbeck, Benjamin E. Turk, Michael B. Yaffe, and Lewis C. Cantley. An atlas of substrate specificities for the human serine/threonine kinome. Nature, 613:759-766, Jan 2023. URL: https://doi.org/10.1038/s41586-022-05575-3, doi:10.1038/s41586-022-05575-3. This article has 416 citations and is from a highest quality peer-reviewed journal.
22. (johnson2023anatlasof pages 4-4): Jared L. Johnson, Tomer M. Yaron, Emily M. Huntsman, Alexander Kerelsky, Junho Song, Amit Regev, Ting-Yu Lin, Katarina Liberatore, Daniel M. Cizin, Benjamin M. Cohen, Neil Vasan, Yilun Ma, Konstantin Krismer, Jaylissa Torres Robles, Bert van de Kooij, Anne E. van Vlimmeren, Nicole Andrée-Busch, Norbert F. Käufer, Maxim V. Dorovkov, Alexey G. Ryazanov, Yuichiro Takagi, Edward R. Kastenhuber, Marcus D. Goncalves, Benjamin D. Hopkins, Olivier Elemento, Dylan J. Taatjes, Alexandre Maucuer, Akio Yamashita, Alexei Degterev, Mohamed Uduman, Jingyi Lu, Sean D. Landry, Bin Zhang, Ian Cossentino, Rune Linding, John Blenis, Peter V. Hornbeck, Benjamin E. Turk, Michael B. Yaffe, and Lewis C. Cantley. An atlas of substrate specificities for the human serine/threonine kinome. Nature, 613:759-766, Jan 2023. URL: https://doi.org/10.1038/s41586-022-05575-3, doi:10.1038/s41586-022-05575-3. This article has 416 citations and is from a highest quality peer-reviewed journal.
23. (king2021utilizingproteolysistargetingchimeras pages 122-126): H King. Utilizing proteolysis-targeting chimeras to target the transcriptional cyclin-dependent kinases 9 and 12. Unknown journal, 2021.
24. (king2021utilizingproteolysistargetingchimeras pages 19-24): H King. Utilizing proteolysis-targeting chimeras to target the transcriptional cyclin-dependent kinases 9 and 12. Unknown journal, 2021.
25. (king2021utilizingproteolysistargetingchimeras pages 8-14): H King. Utilizing proteolysis-targeting chimeras to target the transcriptional cyclin-dependent kinases 9 and 12. Unknown journal, 2021.
26. (ksionsko2024mechanisticcharacterizationof pages 21-23): Nora Anna Maria Ksionsko. Mechanistic Characterization of CDK9 Inhibition in T-Cell Lymphoma. PhD thesis, University Goettingen Repository, 2024. URL: https://doi.org/10.53846/goediss-10686, doi:10.53846/goediss-10686.
27. (mandal2021targetingcdk9for pages 1-2): Ranadip Mandal, Sven Becker, and Klaus Strebhardt. Targeting cdk9 for anti-cancer therapeutics. Cancers, 13:2181, May 2021. URL: https://doi.org/10.3390/cancers13092181, doi:10.3390/cancers13092181. This article has 107 citations and is from a peer-reviewed journal.
28. (mandal2021targetingcdk9for pages 2-4): Ranadip Mandal, Sven Becker, and Klaus Strebhardt. Targeting cdk9 for anti-cancer therapeutics. Cancers, 13:2181, May 2021. URL: https://doi.org/10.3390/cancers13092181, doi:10.3390/cancers13092181. This article has 107 citations and is from a peer-reviewed journal.
29. (mandal2021targetingcdk9for pages 23-25): Ranadip Mandal, Sven Becker, and Klaus Strebhardt. Targeting cdk9 for anti-cancer therapeutics. Cancers, 13:2181, May 2021. URL: https://doi.org/10.3390/cancers13092181, doi:10.3390/cancers13092181. This article has 107 citations and is from a peer-reviewed journal.
30. (mandal2021targetingcdk9for pages 29-30): Ranadip Mandal, Sven Becker, and Klaus Strebhardt. Targeting cdk9 for anti-cancer therapeutics. Cancers, 13:2181, May 2021. URL: https://doi.org/10.3390/cancers13092181, doi:10.3390/cancers13092181. This article has 107 citations and is from a peer-reviewed journal.
31. (mandal2021targetingcdk9for pages 4-5): Ranadip Mandal, Sven Becker, and Klaus Strebhardt. Targeting cdk9 for anti-cancer therapeutics. Cancers, 13:2181, May 2021. URL: https://doi.org/10.3390/cancers13092181, doi:10.3390/cancers13092181. This article has 107 citations and is from a peer-reviewed journal.
32. (martinez2024paf1callostericallyactivates pages 1-5): David Lopez Martinez, Izabela Todorovski, Melvin Noe Gonzalez, Charlotte Rusimbi, Daniel Blears, Nessrine Khallou, Zhong Han, A. Barbara Dirac-Svejstrup, and Jesper Q. Svejstrup. Paf1c allosterically activates cdk12/13 kinase during rnapii transcript elongation. BioRxiv, Oct 2024. URL: https://doi.org/10.1101/2024.10.14.618141, doi:10.1101/2024.10.14.618141. This article has 1 citations.
33. (martinez2024paf1callostericallyactivates pages 20-24): David Lopez Martinez, Izabela Todorovski, Melvin Noe Gonzalez, Charlotte Rusimbi, Daniel Blears, Nessrine Khallou, Zhong Han, A. Barbara Dirac-Svejstrup, and Jesper Q. Svejstrup. Paf1c allosterically activates cdk12/13 kinase during rnapii transcript elongation. BioRxiv, Oct 2024. URL: https://doi.org/10.1101/2024.10.14.618141, doi:10.1101/2024.10.14.618141. This article has 1 citations.
34. (modi2022kincoreaweb pages 3-5): Vivek Modi and Roland L. Dunbrack. Kincore: a web resource for structural classification of protein kinases and their inhibitors. BioRxiv, 50:D654-D664, Feb 2022. URL: https://doi.org/10.1101/2021.02.12.430923, doi:10.1101/2021.02.12.430923. This article has 76 citations.
35. (mohammad2022bioinformaticanalysisof pages 142-145): Eusra Mohammad. Bioinformatic analysis of multi-omics data elucidates transcriptional cyclin dependent kinase mediated transcriptional regulation. PhD thesis, University Goettingen Repository, 2022. URL: https://doi.org/10.53846/goediss-9383, doi:10.53846/goediss-9383.
36. (mohammad2022bioinformaticanalysisof pages 22-26): Eusra Mohammad. Bioinformatic analysis of multi-omics data elucidates transcriptional cyclin dependent kinase mediated transcriptional regulation. PhD thesis, University Goettingen Repository, 2022. URL: https://doi.org/10.53846/goediss-9383, doi:10.53846/goediss-9383.
37. (mohammad2022bioinformaticanalysisof pages 26-29): Eusra Mohammad. Bioinformatic analysis of multi-omics data elucidates transcriptional cyclin dependent kinase mediated transcriptional regulation. PhD thesis, University Goettingen Repository, 2022. URL: https://doi.org/10.53846/goediss-9383, doi:10.53846/goediss-9383.
38. (morales2016overviewofcdk9 pages 1-2): Fatima Morales and Antonio Giordano. Overview of cdk9 as a target in cancer research. Cell Cycle, 15:519-527, Feb 2016. URL: https://doi.org/10.1080/15384101.2016.1138186, doi:10.1080/15384101.2016.1138186. This article has 215 citations and is from a peer-reviewed journal.
39. (paparidis2017theemergingpicture pages 1-2): Nikolas Ferreira dos Santos Paparidis, Maxwell Castro Durvale, and Fernanda Canduri. The emerging picture of cdk9/p-tefb: more than 20 years of advances since pitalre. Molecular bioSystems, 13 2:246-276, Jan 2017. URL: https://doi.org/10.1039/c6mb00387g, doi:10.1039/c6mb00387g. This article has 79 citations and is from a peer-reviewed journal.
40. (paparidis2017theemergingpicture pages 3-4): Nikolas Ferreira dos Santos Paparidis, Maxwell Castro Durvale, and Fernanda Canduri. The emerging picture of cdk9/p-tefb: more than 20 years of advances since pitalre. Molecular bioSystems, 13 2:246-276, Jan 2017. URL: https://doi.org/10.1039/c6mb00387g, doi:10.1039/c6mb00387g. This article has 79 citations and is from a peer-reviewed journal.
41. (paparidis2017theemergingpicture pages 6-8): Nikolas Ferreira dos Santos Paparidis, Maxwell Castro Durvale, and Fernanda Canduri. The emerging picture of cdk9/p-tefb: more than 20 years of advances since pitalre. Molecular bioSystems, 13 2:246-276, Jan 2017. URL: https://doi.org/10.1039/c6mb00387g, doi:10.1039/c6mb00387g. This article has 79 citations and is from a peer-reviewed journal.
42. (parua2020dissectingthepol pages 11-12): Pabitra K. Parua and Robert P. Fisher. Dissecting the pol ii transcription cycle and derailing cancer with cdk inhibitors. Nature Chemical Biology, 16:716-724, Jun 2020. URL: https://doi.org/10.1038/s41589-020-0563-4, doi:10.1038/s41589-020-0563-4. This article has 87 citations and is from a highest quality peer-reviewed journal.
43. (parua2020dissectingthepol pages 16-23): Pabitra K. Parua and Robert P. Fisher. Dissecting the pol ii transcription cycle and derailing cancer with cdk inhibitors. Nature Chemical Biology, 16:716-724, Jun 2020. URL: https://doi.org/10.1038/s41589-020-0563-4, doi:10.1038/s41589-020-0563-4. This article has 87 citations and is from a highest quality peer-reviewed journal.